BB&T Securities LLC Acquires 3,184 Shares of Davita Inc (DVA)
BB&T Securities LLC grew its holdings in Davita Inc (NYSE:DVA) by 84.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,956 shares of the company’s stock after purchasing an additional 3,184 shares during the quarter. BB&T Securities LLC’s holdings in Davita were worth $482,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Vigilant Capital Management LLC raised its holdings in shares of Davita by 250.0% in the 2nd quarter. Vigilant Capital Management LLC now owns 2,100 shares of the company’s stock valued at $146,000 after purchasing an additional 1,500 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of Davita in the 2nd quarter valued at about $206,000. IBM Retirement Fund bought a new stake in shares of Davita in the 1st quarter valued at about $212,000. IFG Advisory LLC bought a new position in shares of Davita during the 2nd quarter worth approximately $213,000. Finally, Jane Street Group LLC bought a new position in shares of Davita during the 1st quarter worth approximately $243,000. Institutional investors and hedge funds own 87.72% of the company’s stock.
NYSE DVA opened at $69.92 on Monday. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.90 and a quick ratio of 1.88. The company has a market cap of $11.67 billion, a P/E ratio of 21.06, a PEG ratio of 1.04 and a beta of 1.10. Davita Inc has a 52 week low of $52.51 and a 52 week high of $80.71.
Several research analysts recently commented on DVA shares. Zacks Investment Research upgraded shares of Davita from a “hold” rating to a “buy” rating and set a $78.00 price objective for the company in a research note on Monday, July 9th. William Blair reiterated a “buy” rating on shares of Davita in a research note on Wednesday, June 6th. Finally, JPMorgan Chase & Co. upgraded shares of Davita from an “underweight” rating to a “neutral” rating in a research note on Thursday, September 13th. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Davita has a consensus rating of “Buy” and an average price target of $82.13.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Article: Index Funds
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.